Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
Completed
Vanda Pharmaceuticals
Phase 3
2005-11-01
The purpose of this study is to determine the safety and efficacy of iloperidone compared to
placebo and an active comparator in the treatment of patients with schizophrenia in acute
exacerbation.
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
Completed
GlaxoSmithKline
Phase 4
2009-07-01
This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in
subjects who have been on an atypical (second-generation) antipsychotic medication. The
investigators hypotheses are that patients who receive Lovaza will experience a significant
decrease in triglycerides from baseline. Secondary hypotheses include: Patients will
experience a significant decrease in total cholesterol, and Lovaza will be well tolerated.
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
Completed
Massachusetts General Hospital
Phase 4
2009-07-01
This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in
subjects who have been on an atypical (second-generation) antipsychotic medication. The
investigators hypotheses are that patients who receive Lovaza will experience a significant
decrease in triglycerides from baseline. Secondary hypotheses include: Patients will
experience a significant decrease in total cholesterol, and Lovaza will be well tolerated.
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
Completed
Novartis
Phase 4
2010-08-01
Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult
subjects with schizophrenia who require a change in their current antipsychotic treatment of
risperidone, olanzapine, or aripiprazole due to suboptimal efficacy and/or
safety/tolerability reasons.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
